The transaction involved 10,000 shares at a weighted-average price of $100.00 per share, totaling $1

Jim Cramer likes Babcock & Wilcox and Smithfield Foods. He also advises taking some profits on B

/C O R R E C T I O N -- BillionToOne/ PR Newswire MENLO PARK, Calif., Aug. 18, 2026 I

BillionToOne, Inc. (Nasdaq: BLLN), a next-generation molecular diagnostics company with a mission to

Study of more than 2,200 pregnant carriers demonstrates strong clinical performance in the intended-

Billiontoone, Inc. (NASDAQ: BLLN - Get Free Report) has been given a consensus rating of "Moderate B

BillionToOne experienced a sharp post-earnings sell-off despite maintaining full-year guidance and s

Gainers Creative Medical Tech (NASDAQ:CELZ) stock increased by 107.8% to $1.39 during Thursday'

Gainers Creative Medical Tech (NASDAQ:CELZ) stock increased by 86.9% to $1.25 during Thursday's

BTIG analyst Mark Massaro maintains BillionToOne (NASDAQ:BLLN) with a Buy and lowers the price ta

BillionToOne stock fell after hours after reporting second-quarter financial results.

While the top- and bottom-line numbers for BillionToOne (BLLN) give a sense of how the business perf

Billiontoone NASDAQ: BLLN reported second-quarter 2026 revenue growth of 64% year over year, driven

Gainers Creative Medical Tech (NASDAQ:CELZ) stock moved upwards by 31.4% to $0.88 during Wednesday&

BillionToOne (NASDAQ:BLLN) affirms FY2026 sales outlook from $450.000 million-$465.000 million to $4

BillionToOne (NASDAQ:BLLN) reported quarterly earnings of $0.15 per share which missed the analyst c

MENLO PARK, Calif., Aug. 05, 2026 (GLOBE NEWSWIRE) -- BillionToOne, Inc. (NASDAQ: BLLN), a next-gene

Renowned physician-scientist, former Director of Frederick National Laboratory, and one of the natio

MENLO PARK, Calif., July 15, 2026 (GLOBE NEWSWIRE) -- BillionToOne, Inc. (NASDAQ: BLLN), a next-gene

According to a Form 4 filing, a BillionToOne executive sold 801 shares of Class A Common Stock at $1

Tom Gardner makes the case for fifty-stock portfolios and AI-powered research, then names five compa

Here is how BillionToOne (BLLN) and Concentra Group (CON) have performed compared to their sector so

BillionToOne's Northstar Response Is a Stronger Predictor of Immunotherapy Outcomes Than Standard-o

Tissue-free ctDNA monitoring was the dominant independent predictor of survival across 12 tumor type

Guggenheim analyst Subbu Nambi initiates coverage on BillionToOne (NASDAQ:BLLN) with a Buy rating

Here is how BillionToOne (BLLN) and Eledon Pharmaceuticals, Inc. (ELDN) have performed compared to t

MENLO PARK, Calif., May 27, 2026 (GLOBE NEWSWIRE) -- BillionToOne, Inc. (NASDAQ: BLLN), a next-gener

During the quarter, we added 9 new positions and exited 11 positions, bringing the number of positio

The average of price targets set by Wall Street analysts indicates a potential upside of 37% in Bill

Cramer likes Silicon Motion, whose shares fell 2.2% to settle at $263.85 on Thursday. Wynn shares de

Guggenheim analyst Subbu Nambi maintains BillionToOne (NASDAQ:BLLN) with a Buy and raises the pri

The mean of analysts' price targets for BillionToOne (BLLN) points to a 25.6% upside in the stock. W

JP Morgan analyst Casey Woodring maintains BillionToOne (NASDAQ:BLLN) with a Overweight and raise

BTIG analyst Mark Massaro maintains BillionToOne (NASDAQ:BLLN) with a Buy and lowers the price ta

BillionToOne (NASDAQ:BLLN) raises FY2026 sales outlook from $430.000 million-$445.000 million to $45

BillionToOne (NASDAQ:BLLN) reported quarterly earnings of $0.34 per share which beat the analyst con

Cramer shared his thoughts on various stocks, calling Joby Aviation too risky, BillionToOne a winner

Summary:Top Wall Street analysts changed outlook on top names. Analyst ratings page shows all chang